Funding for this research was provided by:
Alexion Pharmaceuticals (Alexion Pharmaceuticals)
Article History
Received: 7 November 2022
Accepted: 18 June 2023
First Online: 22 June 2023
Declarations
:
: Not applicable.
: This study received ethical approval from Salus Institutional Review Board (Ref no: ALEX2020).
: Not applicable.
: This study was sponsored by Alexion, AstraZeneca Rare Disease, which also funded medical writing support and provided a formal review. The authors retain control and final authority of manuscript content and decisions. PH, UT, KB & NS declare that they have no personal, commercial, academic or financial conflicts of interest.